Company also announces appointment of Tom Hughes, Boston-based biotech builder and CEO of Navitor Pharmaceuticals, to board of directors.
Company now advancing multiple programs in neurodevelopmental, neurodegenerative and metabolic disorders.
TORONTO – November 5, 2020. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today ...